Effects of adrenomeduline and ramp2 on the lung of mice exposed to total body radiation

Q4 Health Professions

Iranian Journal of Radiation Research Pub Date : 2020-07-10 DOI:10.18869/ACADPUB.IJRR.18.3.571

M. K. Ozbilgin, G. Z. Karaman, S. Gencur, E. Gumustepe, C. Kurtman

{"title":"Effects of adrenomeduline and ramp2 on the lung of mice exposed to total body radiation","authors":"M. K. Ozbilgin, G. Z. Karaman, S. Gencur, E. Gumustepe, C. Kurtman","doi":"10.18869/ACADPUB.IJRR.18.3.571","DOIUrl":null,"url":null,"abstract":"Background: Adrenomedullin (AM) and its receptor, receptor activitymodifying protein (RAMP) 2 have pleiotropic regulatory functions in normal tissue and cancer tissue. AM is produced and secreted both numerous stromal cells and tumor cells. This study aims to investigate a possible role of AM and RAMP2 in the radiation exposure in the normal lung tissue. Materials and Methods: Four groups with 6 male adult Swiss Albino mice per group were investigated. The mice were subjected to a 500 cGy single-dose radiation exposure in the total body radiation device and lung tissues were collected. 1, 2, and 7 days after radiation exposure, with 1 reference group which was not exposed to radiation. Results: The general histology and the immunohistochemistry of the tissue samples prepared with antiAM, anti– RAMP2, and monoclonal antibodies were investigated, yielding a statistically significant increase for AM on day 3 and for RAMP2 on day 1 after radiation exposure. Conclusion: The observed increase of AM and RAMP2 concentrations in the normal tissue matrix after radiation exposure may play a role in the side effects of radiotherapy.","PeriodicalId":14498,"journal":{"name":"Iranian Journal of Radiation Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Radiation Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18869/ACADPUB.IJRR.18.3.571","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Health Professions","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Adrenomedullin (AM) and its receptor, receptor activitymodifying protein (RAMP) 2 have pleiotropic regulatory functions in normal tissue and cancer tissue. AM is produced and secreted both numerous stromal cells and tumor cells. This study aims to investigate a possible role of AM and RAMP2 in the radiation exposure in the normal lung tissue. Materials and Methods: Four groups with 6 male adult Swiss Albino mice per group were investigated. The mice were subjected to a 500 cGy single-dose radiation exposure in the total body radiation device and lung tissues were collected. 1, 2, and 7 days after radiation exposure, with 1 reference group which was not exposed to radiation. Results: The general histology and the immunohistochemistry of the tissue samples prepared with antiAM, anti– RAMP2, and monoclonal antibodies were investigated, yielding a statistically significant increase for AM on day 3 and for RAMP2 on day 1 after radiation exposure. Conclusion: The observed increase of AM and RAMP2 concentrations in the normal tissue matrix after radiation exposure may play a role in the side effects of radiotherapy.

查看原文本刊更多论文

肾上腺素和ramp2对全身辐射小鼠肺部的影响

背景:肾上腺髓质素(AM)及其受体受体活性修饰蛋白(RAMP) 2在正常组织和肿瘤组织中具有多效性调节功能。AM在许多基质细胞和肿瘤细胞中都有产生和分泌。本研究旨在探讨AM和RAMP2在正常肺组织辐射暴露中的可能作用。材料与方法:分为4组，每组6只雄性成年瑞士白化小鼠。小鼠在全身辐射装置中接受500 cGy单剂量辐射照射，并收集肺组织。照射后1、2、7天，1个参照组未照射。结果:对抗AM、抗RAMP2和单克隆抗体制备的组织样本进行一般组织学和免疫组织化学分析，发现辐射后第3天AM和第1天RAMP2的表达均有统计学意义的增加。结论:放疗后正常组织基质中AM和RAMP2浓度的升高可能与放疗副反应有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Iranian Journal of Radiation Research RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

CiteScore

0.67

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Iranian Journal of Radiation Research (IJRR) publishes original scientific research and clinical investigations related to radiation oncology, radiation biology, and Medical and health physics. The clinical studies submitted for publication include experimental studies of combined modality treatment, especially chemoradiotherapy approaches, and relevant innovations in hyperthermia, brachytherapy, high LET irradiation, nuclear medicine, dosimetry, tumor imaging, radiation treatment planning, radiosensitizers, and radioprotectors. All manuscripts must pass stringent peer-review and only papers that are rated of high scientific quality are accepted.